<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increases in the level of cyclooxygenase (COX)-2 and <z:chebi fb="0" ids="26347">prostanoids</z:chebi> such as <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) (<z:chebi fb="0" ids="26338">PGE</z:chebi>(2)) are considered biomarkers of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) have been used to reduce the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development by reducing <z:chebi fb="0" ids="26347">prostanoid</z:chebi> biosynthesis as COX inhibitors </plain></SENT>
<SENT sid="2" pm="."><plain>Along with their activity as COX inhibitors, <z:chebi fb="1" ids="35475">NSAID</z:chebi> have been reported to have other effects </plain></SENT>
<SENT sid="3" pm="."><plain>One major <z:chebi fb="1" ids="35475">NSAID</z:chebi>, <z:chebi fb="0" ids="49662">indomethacin</z:chebi>, has been shown to have several effects independent of COX inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>To further examine the COX-inhibition-independent effects of <z:chebi fb="0" ids="49662">indomethacin</z:chebi> on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, we used human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> LS174T cells, known to have express little COX-2 and have no detectable <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) production </plain></SENT>
<SENT sid="5" pm="."><plain>Here we show that <z:chebi fb="0" ids="49662">indomethacin</z:chebi> has a potential antagonizing effect on human EP(2) receptors </plain></SENT>
<SENT sid="6" pm="."><plain>We believe this study raises the reasons to use <z:chebi fb="0" ids="49662">indomethacin</z:chebi> as a lead-compound for setting up another EP(2) receptor-specific <z:chebi fb="68" ids="48706">antagonist</z:chebi> as a relatively cost-efficient strategy for anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> medication in the future </plain></SENT>
</text></document>